{"entity":{"id":"nct06631092","kind":"trial","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of Oral DNA Vaccine in triple-negative breast cancer, run by NEC Bio B.V, now recruiting.","summary":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer is a phase 1/2 interventional study registered as NCT06631092 by NEC Bio B.V, with 28 participants planned, started 2024-11-20 and due to reach its primary completion in 2027-12-31. Interventions recorded: Oral DNA Vaccine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06631092","url":"https://clinicaltrials.gov/study/NCT06631092"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc","tnbc-early"],"sections":[],"technologies":[],"targets":["pd1"],"drugs":[],"companies":["nec-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06631092","phase":"1/2","setting":"An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 as add-on to First-line Neoadjuvant Anti-PD-1 Monoclonal Antibody Therapy in Patients With Triple-negative Breast Cancer","sponsor":"NEC Bio B.V","participation":[{"nct":"NCT06631092","source":"https://clinicaltrials.gov/study/NCT06631092","fetchedAt":"2026-10-07T16:54:51.841Z","studySha256":"a43399355ab72d1e0c32bad36a3f4aff77cab1ec8508d4a6b9f31c65ddd331c2","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-26","leadSponsor":"NEC Bio B.V","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":28,"enrolmentType":"ESTIMATED","siteCount":2,"recruitingSiteCount":2,"countries":["Germany"]}],"started":"2024-11-20","startedType":"actual","enrolled":28,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06631092/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"company":[{"id":"nec-bio","kind":"company","name":"NEC Bio","route":"/companies/nec-bio/"}]}}